Publication
Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas
dc.contributor.author | Araujo-Castro, Marta | |
dc.contributor.author | Biagetti, Betina | |
dc.contributor.author | Menéndez, Edelmiro | |
dc.contributor.author | Novoa-Testa, Iría | |
dc.contributor.author | Cordido, Fernando | |
dc.contributor.author | Berrocal, Víctor Rodríguez | |
dc.contributor.author | Pascual-Corrales, Eider | |
dc.contributor.author | Guerrero-Pérez, Fernando | |
dc.contributor.author | Vicente, Almudena | |
dc.contributor.author | García-Centeno, Rogelio | |
dc.contributor.author | González, Laura | |
dc.contributor.author | García, María Dolores Ollero | |
dc.contributor.author | Echarri, Ana Irigaray | |
dc.contributor.author | Rodríguez, María Dolores Moure | |
dc.contributor.author | Novo-Rodríguez, Cristina | |
dc.contributor.author | Calatayud, María | |
dc.contributor.author | Villar-Taibo, Rocío | |
dc.contributor.author | Bernabéu, Ignacio | |
dc.contributor.author | Alvarez-Escola, Cristina | |
dc.contributor.author | Jimenéz, Carmen Tenorio | |
dc.contributor.author | Abellán-Galiana, Pablo | |
dc.contributor.author | Venegas, Eva | |
dc.contributor.author | González-Molero, Inmaculada | |
dc.contributor.author | Iglesias, Pedro | |
dc.contributor.author | Blanco, Concepción | |
dc.contributor.author | Lara, Fernando Vidal Ostos de | |
dc.contributor.author | Novoa, María Paz de Miguel | |
dc.contributor.author | Torres, Elena López Mezquita | |
dc.contributor.author | Hanzu, Felicia | |
dc.contributor.author | Lamas, Cristina | |
dc.contributor.author | Rodríguez, Silvia Aznar | |
dc.contributor.author | Aulinas, Anna | |
dc.contributor.author | Recio, José María | |
dc.contributor.author | Aviles-Pérez, María Dolores | |
dc.contributor.author | Núñez, Miguel Antonio Sampedro | |
dc.contributor.author | Camara, Rosa | |
dc.contributor.author | Fano, Miguel Paja | |
dc.contributor.author | Fajardo, Carmen | |
dc.contributor.author | Cardoso, Luís | |
dc.contributor.author | Marques, Pedro | |
dc.contributor.author | Martínez-Sáez, Elena | |
dc.contributor.author | Ruz-Caracuel, Ignacio | |
dc.contributor.author | Marazuela, Mónica | |
dc.contributor.author | Puig-Domingo, Manel | |
dc.date.accessioned | 2025-08-13T09:42:25Z | |
dc.date.available | 2025-08-13T09:42:25Z | |
dc.date.issued | 2025-07-15 | |
dc.description.abstract | Aim: To evaluate which factors are associated with a higher probability of failure to surgical and first-generation somatostatin receptor ligands (fgSRLs) treatment in patients with growth hormone and prolactin co-secreting pituitary adenomas (GH&PRL-PAs). Methods: Acromegaly patients with GH&PRL-PAs included in the ACRO-SPAIN study were enrolled. GH&PRL-PAs were defined as tumors with serum PRL levels above the upper limit of normal and positive immunostaining for GH and PRL, or with PRL levels ≥100 ng/mL when immunostaining data were not available. Results: A total of 126 acromegaly patients with GH&PRL-PAs who underwent transsphenoidal pituitary surgery were included, and 42.1% (n = 53) were biochemically cured at the immediate postoperative evaluation. Knosp grade >2 (odds ratio (OR) 3.48, 95% CI 1.28–9.38), higher serum GH (OR 1.01, 95% CI 1.01–1.08) and IGF-1 (OR 1.60, 95% CI 1.05–2.45) levels were associated with a lower probability of surgical cure. Sixty-eight patients received first-line medical therapy as follows: fgSRLs in monotherapy (n = 22), fgSRL plus cabergoline (n = 37), cabergoline in monotherapy (n = 7) and pegvisomant in monotherapy (n = 2). Among the cases treated with fgSRL in monotherapy, 18.2% (n = 4/22) were resistant. We identified as predictors of fgSRL resistance (in monotherapy and combined with cabergoline) a Knosp grade >2 (OR 8.75, P = 0.003), high GH levels at acromegaly diagnosis (OR 1.02, P = 0.031) and higher postoperative GH levels (OR 1.05, P = 0.006), but no predictors of response to fgSRL in monotherapy were identified. Conclusion: The clinical predictors of surgical failure and of fgSRL resistance in patients with GH&PRL-PAs are similar to those described in acromegaly without PRL, co-secretion. | eng |
dc.identifier.doi | 10.1530/EC-25-0103 | |
dc.identifier.eid | 105012021956 | |
dc.identifier.other | 71b22915-e0fe-4c0c-b26f-9eec9916d6cc | |
dc.identifier.pmc | PMC12268987 | |
dc.identifier.pmid | 40590355 | |
dc.identifier.uri | http://hdl.handle.net/10400.14/54495 | |
dc.language.iso | eng | |
dc.peerreviewed | yes | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Acromegaly | |
dc.subject | Growth hormone | |
dc.subject | Prolactin co-secreting pituitary adenoma | |
dc.subject | Somatostatin receptor ligands | |
dc.subject | Surgical remission | |
dc.title | Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas | eng |
dc.type | research article | |
dspace.entity.type | Publication | |
oaire.citation.issue | 7 | |
oaire.citation.title | Endocrine Connections | |
oaire.citation.volume | 14 | |
oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |
Files
Original bundle
1 - 1 of 1